risedronic acid has been researched along with Osteoarthritis, Hip in 2 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Osteoarthritis, Hip: Noninflammatory degenerative disease of the hip joint which usually appears in late middle or old age. It is characterized by growth or maturational disturbances in the femoral neck and head, as well as acetabular dysplasia. A dominant symptom is pain on weight-bearing or motion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Comorbid factors such as ischemic heart disease, hip osteoarthritis, and higher values of FRAX blunted the effects of QOL of the treatment." | 1.38 | The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. ( Hayakawa, Y; Iinuma, N; Itoh, M; Iwayama, S; Kamisaki, T; Nakamura, T; Nishikawa, M; Osawa, M; Suzuki, H; Yamaguchi, H, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muren, O | 1 |
| Akbarian, E | 1 |
| Salemyr, M | 1 |
| Bodén, H | 1 |
| Eisler, T | 1 |
| Stark, A | 1 |
| Sköldenberg, O | 1 |
| Nakamura, T | 1 |
| Osawa, M | 1 |
| Itoh, M | 1 |
| Yamaguchi, H | 1 |
| Iinuma, N | 1 |
| Hayakawa, Y | 1 |
| Suzuki, H | 1 |
| Kamisaki, T | 1 |
| Iwayama, S | 1 |
| Nishikawa, M | 1 |
1 trial available for risedronic acid and Osteoarthritis, Hip
| Article | Year |
|---|---|
No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial.
Topics: Absorptiometry, Photon; Adult; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Cons | 2015 |
1 other study available for risedronic acid and Osteoarthritis, Hip
| Article | Year |
|---|---|
The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; Comorbidity; | 2012 |